In this March 16, 2020 file photo, a patient receives a shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, at the Kaiser Permanente Washington Health Research Institute in Seattle. (TED S. WARREN / AP)

Drugmakers racing to produce COVID-19 vaccines pledged to avoid shortcuts on science as they face pressure to rush a shot to market.

Public trust in a vaccine will be crucial as public health authorities try to convince millions of healthy people around the world to take it

In an unusual public letter, the companies agreed to submit the vaccines for clearance only when they’re shown to be safe and effective in large clinical studies. 

ALSO READ: 4 Chinese COVID-19 vaccines undergoing phase-3 clinical trials

The chief executive officers of nine frontrunners in the push for a coronavirus inoculation signed the pledge: AstraZeneca Plc, BioNTech SE, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co, Moderna Inc, Novavax Inc, Pfizer Inc and Sanofi.

“In the interest of public health, we pledge to always make the safety and well-being of vaccinated individuals our top priority,” the executives wrote.

The document is intended to counter perceptions that political pressure to deliver a shot as soon as possible may compromise its safety. US President Donald Trump has said a vaccine could be ready before the presidential election in November, and has accused the Food and Drug Administration (FDA) of slowing its work to hurt him politically.

ALSO READ: UAE to host phase 3 trials for Chinese vaccine

Public trust in a vaccine will be crucial as public health authorities try to convince millions of healthy people around the world to take it. The pledge also included a promise that companies would work to ensure there are vaccine options “suitable for global access.”

Squeezed Timeline

Drugmakers have condensed the development timeline for their vaccines -- normally a matter of years -- down to months, with early results from some of the frontrunners expected before the end of the year. Pfizer has said it could have crucial test readings by October.

The companies said they would meet FDA expectations for studies with participants across diverse populations. 

ALSO READ: Chinese vaccine starts phase-3 clinical trials in Argentina

Moderna recently slowed the enrollment of its trial, resulting in a delay of about a week, in order to recruit more people from minority communities at high risk from the virus, CNBC has reported.

Any data that form the basis of an emergency-use authorization for a vaccine should be made public, Merck CEO Ken Frazier said last week. 

“The scientific community can actually pore through that data and assure the public that it has been looked at objectively,” Frazier said at a meeting of pharma manufacturers.

READ MORE: Morocco to test Chinese virus vaccine in phase 3 trial